Transfusion reactions associated with <scp>COVID</scp>‐19 convalescent plasma therapy for <scp>SARS‐CoV</scp>‐2

Abstract

Our findings support the use of CP as a safe, therapeutic option from a transfusion reaction perspective, in the setting of COVID-19. Further studies are needed to confirm the clinical significance of ABO group B, age, and predisposing disease severity in the incidence of transfusion reaction events.